A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

PHASE4CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

August 19, 2022

Study Completion Date

August 26, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

Empagliflozin

DRUG

Placebo

Placebo

Trial Locations (18)

451-8511

Meitetsu Hospital, Aichi, Nagoya

455-8530

Chubu Rosai Hospital, Aichi, Nagoya

457-8511

Daido Hospital, Aichi, Nagoya

963-8851

Seino Internal Medicine Clinic, Fukushima, Koriyama

501-1194

Gifu University Hospital, Gifu, Gifu

662-0971

Watanabe Clinic, Hyogo, Nishinomiya

231-0023

Institute Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic, Kanagawa, Yokohama

600-8898

Medical Corporation KEISEIKAI Kajiyama Clinic, Kyoto, Kyoto

615-8125

Medical Corporation Hayashi Katagihara Clinic, Kyoto, Kyoto

311-4153

Iryouhouijneiwakai Minamiakatsuka Clinic, Mito, Ibaraki

302-0118

Moriya Keiyu Hospital, Moriya, Ibaraki

399-8695

North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun

384-8588

Asama Nanroku Komoro Medical Center, Nagano, Komoro

343-8577

Koshigaya Municipal Hospital, Saitama, Koshigaya

101-0041

Dojinkinenkai Meiwa Hospital, Tokyo, Chiyoda-ku

104-0031

Tokyo Asbo Clinic, Tokyo, Chuo-ku

108-0075

Shinagawa East one Medical Clinic, Tokyo, Minato-ku

171-0021

Ikebukuro Metropolitan Clinic, Tokyo, Toshima-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY